Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
14.85
-0.04 (-0.27%)
At close: May 30, 2025, 4:00 PM
14.15
-0.70 (-4.71%)
After-hours: May 30, 2025, 7:13 PM EDT
Company Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia.
Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 207 |
| CEO | Eric Venker |
Contact Details
Address: 320 West 37th Street, 6th Floor New York, New York 10018 United States | |
| Phone | 917 580 3099 |
| Website | immunovant.com |
Stock Details
| Ticker Symbol | IMVT |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001764013 |
| CUSIP Number | 45258J102 |
| ISIN Number | US45258J1025 |
| Employer ID | 83-2771572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric Venker M.D., Pharm.D. | Chief Executive Officer and Director |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Dr. Jay S. Stout Ph.D. | Chief Technology Officer |
| Tiago M. Girao CPA | Chief Financial Officer |
| Melanie Gloria B.S.N. | Chief Operating Officer |
| Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Lauren Schrier M.B.A. | Vice President of Marketing |
| Christine Blodgett | Senior Vice President of Human Resources |
| Andy Deig | Senior Vice President of Strategic Finance |
| Dr. Michael Geffner M.B.A., M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 29, 2025 | 10-K | Annual Report |
| May 29, 2025 | 8-K | Current Report |
| May 21, 2025 | 144 | Filing |
| May 19, 2025 | 144 | Filing |
| Apr 30, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 21, 2025 | SCHEDULE 13D/A | Filing |
| Apr 21, 2025 | 8-K | Current Report |
| Mar 26, 2025 | SCHEDULE 13G | Filing |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 7, 2025 | 144 | Filing |